Related Experiment Video

Updated: May 26, 2026

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

Update on PARP1 inhibitors in ovarian cancer

C Sessa1

  • 1Oncology Institute of Southern Switzerland, San Giovanni Hospital, Bellinzona, Switzerland. cristiana.sessa@eoc.ch

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|December 20, 2011
PubMed

Insights

PARP inhibitors show promise for treating BRCA-deficient tumors, including ovarian cancers. Research now expands to

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The development of Poly (ADP-ribose) polymerase (PARP) inhibitors is rooted in the synthetic lethality principle for treating BRCA1/BRCA2-deficient tumors.
  • Initial studies with olaparib demonstrated efficacy in BRCA mutation carriers, expanding the potential patient population for PARP inhibitor therapy.

Purpose of the Study:

  • To review the clinical development of PARP inhibitors, focusing on their efficacy in BRCA-deficient and 'BRCAness' tumors.
  • To highlight the ongoing research into identifying the BRCAness phenotype and developing diagnostic tests.
  • To discuss future directions for optimizing PARP inhibitor combinations with other therapies.

Main Methods:

  • Review of clinical data and preclinical studies on PARP inhibitors, particularly olaparib.
  • Analysis of treatment responses in BRCA mutation carriers and patients with homologous recombination deficiency (BRCAness).

Main Results:

  • Objective responses to olaparib observed in platinum-sensitive and platinum-resistant BRCA mutation carriers.
  • Efficacy of olaparib demonstrated in BRCA-negative patients with homologous recombination dysfunction ('BRCAness').
  • Olaparib maintenance therapy shows antitumor effects in BRCAness patients with recurrent high-grade serous ovarian cancer.

Conclusions:

  • PARP inhibitors are effective in BRCA-mutated and BRCAness ovarian cancers.
  • Identifying the BRCAness phenotype is crucial for patient selection.
  • Further preclinical research is needed to optimize combination regimens with PARP inhibitors and other agents.

More Related Videos

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...